Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Latanoprost 50 µg/ml Eye Drops vs. Xalatan in Open-Angle Glaucoma
2011-002601-30Phase 3Completed
- Sponsor
- OmniVision
- Start
- Jul 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of latanoprost in open-angle glaucoma (OAG) (2 arms), sponsored by OmniVision. Primary endpoint: Interocular pressure (IOP). Started Jul 2011; status: completed.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2011-002601-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002601-30.